Patients who will be acquiring cyclosporine, tacrolimus or other agents to circumvent graft-as opposed to-host illness write-up bone marrow transplant are certainly not eligible for this trial Experimental: Dose expansion_sub-populace 2_lower dose of niraparib MTDs and/or prospect RP2Ds for elimusertib applied in combination with niraparib in a decrease fixed dose. https://cdk9-in-284173.kylieblog.com/27190115/little-known-facts-about-obeticholic-acid